glp 1 increase insulin secretion GLP-1 is released from the small intestine after meal ingestion and GLP-1 RA education

However, doctors may sometimes prescribe this drug off-label for weight management

Despite lower efficacy and tolerability shown by nasally administered PYY agonists in early studies, long-acting subcutaneous PYY receptor agonists such as PYY 1875 are undergoing early-phase clinical trials to evaluate their safety and effectiveness as monotherapy or in combination with GLP-1 receptor agonists for the treatment of obesity

This may be attributed to muscle strength loss and reduction in physical efficiency along with the accompanied risk of developing insulin resistance if lean mass is diminished [164]

Medical Weight Loss Explore physician-guided medical weight loss in Lakeland, FL for eligible adults interested in GLP-1 weight loss injections, Tirzepatide, Semaglutide, Mounjaro, Zepbound, Wegovy, Ozempic, appetite support, metabolic health, and long-term weight management

But the strength of a mechanistic argument does not override the need for careful clinical judgment, and both therapeutic approaches carry risk profiles that must be understood and managed individually

Hi friends